Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

Posted on May 10, 2022

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent business and pipeline progress, and reported financial results for the first quarter 2022.

Categories: In the News

Leave a Reply

Your email address will not be published.